In fact, preliminary studies have confirmed the effectiveness of tocilizumab in severe COVID-19 patients 37-40, and a recent publication has demonstrated that impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 41, further supporting the hypothesis that targeting IL-6 signaling pathways could be a potential promise for severe and critical COVID-19 patients. Here, IL6 is linked to COVID-19.